摘要
目的观察急性冠脉综合征(ACS)患者于多个支架置入术后应用国产氯吡格雷的临床疗效和安全性。方法入选166例本院自2006年10年至2008年3至诊断为ACS行PCI治疗的患者,每个患者置入支架数均≥2个,所有患者均接受ACS常规治疗,分为两组,分别于术前给予300mg负荷量、术后长期给予每日75mg维持剂量的国产氯吡格雷(泰嘉)和进口氯吡格雷(波立维),随访术后6个月内,观察主要临床心血管事件和出血事件的发生情况。结果两组患者基线特征、冠脉造影及PCI特征均无明显统计学差异(P>0.05);术后随访6个月内两组患者均未出现心源性死亡、恶性心律失常及颅内出血、消化道大出血等严重出血事件,两组患者临床心血管事件比较未见统计学意义。结论ACS患者多支架植入术后应用国产氯吡格雷(泰嘉)进行抗血小板治疗,与同类进口药物波立维相比,在临床有效性及安全性方面的效果肯定,具有较高的效价比。
Objective To observe the therapeutic effect of domestic clopidogrel on patients with acute coronary syndrome （ACS） after muhi-stents-planted percutaneous coronary intervention. Methods From October 2006 to March 2008,166 patients with ACS admitted in the department of cardiology of Nanjing Drum Tower Hospital were included, and more than two stents were implanted in each patient. All patients were treated with routine pharmacotherapeutics regimen, and they were divided into two groups： domestic clopidogrel （ TALCOM） group and imported clopidogrel （PLAVIX） group,while each patient took a loading dose of 300 mg before PCI and a maintenance dose of 75 mg domestic or imported clopidogrel after PCI respectively. The incidence of major clinical cardiovascular events （ MACE ） and hemorrhagic events were followed up during 6 months after PCI procedure. Results There were no statistic differences in baseline and PCI characteristic between two groups（P 〉 0. 05）. During six-month follow-up, there were no differences in the occurrence rate of major clinical cardiovascular events and hemorrhagic events between two groups （P 〉 0. 05 ）. Concbmions As adjunctive treatment of multi-stents-planted PCI in patients with ACS, TALCOM and PLAVIX has the similar efficiency of anti-platelet. Comparing with the PLAVIX, the efficacy and safety of TALCOM has been confirmed in this study.
出处
《中国现代药物应用》
2009年第24期20-22,共3页
Chinese Journal of Modern Drug Application
